<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wells TJ</submitter><funding>Medical Research Council</funding><funding>Biotechnology and Biological Sciences Research Council</funding><pagination>1893-904</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4144740</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>211(9)</volume><pubmed_abstract>Although specific antibody induced by pathogens or vaccines is a key component of protection against infectious threats, some viruses, such as dengue, induce antibody that enhances the development of infection. In contrast, antibody-dependent enhancement of bacterial infection is largely unrecognized. Here, we demonstrate that in a significant portion of patients with bronchiectasis and Pseudomonas aeruginosa lung infection, antibody can protect the bacterium from complement-mediated killing. Strains that resist antibody-induced, complement-mediated killing produce lipopolysaccharide containing O-antigen. The inhibition of antibody-mediated killing is caused by excess production of O-antigen-specific IgG2 antibodies. Depletion of IgG2 to O-antigen restores the ability of sera to kill strai</pubmed_abstract><journal>The Journal of experimental medicine</journal><pubmed_title>Increased severity of respiratory infections associated with elevated anti-LPS IgG2 which inhibits serum bactericidal killing.</pubmed_title><pmcid>PMC4144740</pmcid><funding_grant_id>MC_PC_13057</funding_grant_id><funding_grant_id>G0701275</funding_grant_id><funding_grant_id>MR/L011263/1</funding_grant_id><funding_grant_id>BB/L004461/1</funding_grant_id><pubmed_authors>Sevastsyanovich YR</pubmed_authors><pubmed_authors>Cunningham AF</pubmed_authors><pubmed_authors>Browning DF</pubmed_authors><pubmed_authors>Heath JN</pubmed_authors><pubmed_authors>Goodall M</pubmed_authors><pubmed_authors>O'Shea MK</pubmed_authors><pubmed_authors>Henderson IR</pubmed_authors><pubmed_authors>Whitters D</pubmed_authors><pubmed_authors>Cranston A</pubmed_authors><pubmed_authors>MacLennan CA</pubmed_authors><pubmed_authors>Wells TJ</pubmed_authors><pubmed_authors>Pravin J</pubmed_authors><pubmed_authors>De Soyza A</pubmed_authors><pubmed_authors>Stockley RA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Increased severity of respiratory infections associated with elevated anti-LPS IgG2 which inhibits serum bactericidal killing.</name><description>Although specific antibody induced by pathogens or vaccines is a key component of protection against infectious threats, some viruses, such as dengue, induce antibody that enhances the development of infection. In contrast, antibody-dependent enhancement of bacterial infection is largely unrecognized. Here, we demonstrate that in a significant portion of patients with bronchiectasis and Pseudomonas aeruginosa lung infection, antibody can protect the bacterium from complement-mediated killing. Strains that resist antibody-induced, complement-mediated killing produce lipopolysaccharide containing O-antigen. The inhibition of antibody-mediated killing is caused by excess production of O-antigen-specific IgG2 antibodies. Depletion of IgG2 to O-antigen restores the ability of sera to kill strai</description><dates><release>2014-01-01T00:00:00Z</release><publication>2014 Aug</publication><modification>2025-05-31T23:13:02.973Z</modification><creation>2025-05-31T23:13:02.973Z</creation></dates><accession>S-EPMC4144740</accession><cross_references><pubmed>25113975</pubmed><doi>10.1084/jem.20132444</doi></cross_references></HashMap>